Clinical Response to Multi-indication Intralesional Immunotherapy for Malignant Melanoma View PDF https://d1io3yog0oux5.cloudfront.net/_990f4fa3e396222b16458f9091bbe91c/morphogenesisinc/db/2306/20852/pdf/VCS+Clinical+Poster+FInal_MG_20160930+Amanda+Laubscher.pdf
T Cell Immune Response to Multi-Indication Intralesional Immunotherapy for Malignant Melanoma View PDF https://d1io3yog0oux5.cloudfront.net/_990f4fa3e396222b16458f9091bbe91c/morphogenesisinc/db/2306/20851/pdf/VCS+INFg+Poster+Final+10.10.2016+Amanda+Laubscher.pdf
Modular, disposable system to enable mass capture of circulating tumor cells View PDF https://d1io3yog0oux5.cloudfront.net/_990f4fa3e396222b16458f9091bbe91c/morphogenesisinc/db/2306/20850/pdf/CellSeeker+Poster+Amanda+Laubscher.pdf
Clinical Phase I Trial: Intralesional Immunotherapy with IFx Hu2.0 (pAc/ emm55 ) Vaccine in Patients with Advanced Merkel Cell Carcinoma or Cutaneous Squamous Cell Carcinoma View PDF https://d1io3yog0oux5.cloudfront.net/_990f4fa3e396222b16458f9091bbe91c/morphogenesisinc/db/2306/20849/pdf/MCC_MCCSymposium_Poster_20191017+Amanda+Laubscher.pdf
Phase 1 Trial: Intralesional Immunotherapy with IFx-Hu2.0 Vaccine in Patients with Advanced Merkel Cell or Cutaneous Squamous Cell Carcinoma View PDF https://d1io3yog0oux5.cloudfront.net/_990f4fa3e396222b16458f9091bbe91c/morphogenesisinc/db/2306/20848/pdf/MCC-cSCC+2019+Poster+Amanda+Laubscher.pdf